InSite Vision now trading OTCBB
InSite Vision (Alameda, California) said that its securities are now eligible for quotation and trading on the Over-the-Counter Bulletin Board (OTCBB) under the new trading symbol "INSV." The Maxim Group is the market maker and assisted the company with the qualification process.
InSite says it is recognized for the discovery and development of novel ocular pharmaceutical products based on its DuraSite bioadhesive polymer core technology, an innovative platform that extends the duration of drug delivery on the eye's surface, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs.
ReGen reports first Menaflex surgery
ReGen Biologics (Hackensack, New Jersey) said that the first commercial surgery in the U.S. using its Menaflex collagen meniscus implant was completed.
The surgery was performed at Jewish Hospital & St. Mary's HealthCare (Louisville, Kentucky) by David Caborn, MD, for a patient who had a partial meniscectomy four years previously.
Caborn said of the procedure, "The Menaflex implant represents a much needed new treatment option for patients with meniscus deficiency. I am excited about the potential for the Menaflex procedure to decrease pain, improve function and decrease the reoperation rate in this patient population."